Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Enliven Therapeutics Inc ELVN

Healthcare
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ELVN)

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

GlobeNewswire April 11, 2024

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

GlobeNewswire April 9, 2024

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

GlobeNewswire March 28, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

GlobeNewswire March 19, 2024

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire March 14, 2024

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

GlobeNewswire February 27, 2024

Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire November 9, 2023

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire August 10, 2023

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire May 31, 2023
View More News ››

Opinion & Analysis (NDAQ:ELVN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ELVN)

Be the first to post on this bullboard.

Pampa Metals Corp.

Pampa Metals Corp.

Pampa Metals is a CSE listed copper porphyry exploration company whose flagship project is the Piuquenes Copper-Gold-Silver ...
View More »